171 related articles for article (PubMed ID: 31601997)
1. Identification of a novel oncogenic mutation of FGFR4 in gastric cancer.
Futami T; Kawase T; Mori K; Asaumi M; Kihara R; Shindoh N; Kuromitsu S
Sci Rep; 2019 Oct; 9(1):14627. PubMed ID: 31601997
[TBL] [Abstract][Full Text] [Related]
2. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.
Taylor JG; Cheuk AT; Tsang PS; Chung JY; Song YK; Desai K; Yu Y; Chen QR; Shah K; Youngblood V; Fang J; Kim SY; Yeung C; Helman LJ; Mendoza A; Ngo V; Staudt LM; Wei JS; Khanna C; Catchpoole D; Qualman SJ; Hewitt SM; Merlino G; Chanock SJ; Khan J
J Clin Invest; 2009 Nov; 119(11):3395-407. PubMed ID: 19809159
[TBL] [Abstract][Full Text] [Related]
3. The leukemia inhibitory factor regulates fibroblast growth factor receptor 4 transcription in gastric cancer.
Di Giorgio C; Bellini R; Lupia A; Massa C; Urbani G; Bordoni M; Marchianò S; Rosselli R; De Gregorio R; Rapacciuolo P; Sepe V; Morretta E; Monti MC; Moraca F; Cari L; Ullah KRS; Natalizi N; Graziosi L; Distrutti E; Biagioli M; Catalanotti B; Donini A; Zampella A; Fiorucci S
Cell Oncol (Dordr); 2024 Apr; 47(2):695-710. PubMed ID: 37945798
[TBL] [Abstract][Full Text] [Related]
4. Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).
Li SQ; Cheuk AT; Shern JF; Song YK; Hurd L; Liao H; Wei JS; Khan J
PLoS One; 2013; 8(10):e76551. PubMed ID: 24124571
[TBL] [Abstract][Full Text] [Related]
5. Silencing of FGFR4 could influence the biological features of gastric cancer cells and its therapeutic value in gastric cancer.
Ye Y; Jiang D; Li J; Wang M; Han C; Zhang X; Zhao C; Wen J; Kan Q
Tumour Biol; 2016 Mar; 37(3):3185-95. PubMed ID: 26432329
[TBL] [Abstract][Full Text] [Related]
6. Combination of the FGFR4 inhibitor PD173074 and 5-fluorouracil reduces proliferation and promotes apoptosis in gastric cancer.
Ye YW; Hu S; Shi YQ; Zhang XF; Zhou Y; Zhao CL; Wang GJ; Wen JG; Zong H
Oncol Rep; 2013 Dec; 30(6):2777-84. PubMed ID: 24126887
[TBL] [Abstract][Full Text] [Related]
7. The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells.
Roidl A; Foo P; Wong W; Mann C; Bechtold S; Berger HJ; Streit S; Ruhe JE; Hart S; Ullrich A; Ho HK
Oncogene; 2010 Mar; 29(10):1543-52. PubMed ID: 19946327
[TBL] [Abstract][Full Text] [Related]
8. The over-expression of FGFR4 could influence the features of gastric cancer cells and inhibit the efficacy of PD173074 and 5-fluorouracil towards gastric cancer.
Li J; Ye Y; Wang M; Lu L; Han C; Zhou Y; Zhang J; Yu Z; Zhang X; Zhao C; Wen J; Kan Q
Tumour Biol; 2016 May; 37(5):6881-91. PubMed ID: 26662569
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor receptor-4 mediates activation of Nuclear Factor Erythroid 2-Related Factor-2 in gastric tumorigenesis.
Soutto M; Zhang X; Bhat N; Chen Z; Zhu S; Maacha S; Genoula M; El-Gazzaz O; Peng D; Lu H; McDonald OG; Chen XS; Cao L; Xu Z; El-Rifai W
Redox Biol; 2024 Feb; 69():102998. PubMed ID: 38154380
[TBL] [Abstract][Full Text] [Related]
10. FGFR4 Gly388Arg Polymorphism Affects the Progression of Gastric Cancer by Activating STAT3 Pathway to Induce Epithelial to Mesenchymal Transition.
Ye Y; Li J; Jiang D; Li J; Xiao C; Li Y; Han C; Zhao C
Cancer Res Treat; 2020 Oct; 52(4):1162-1177. PubMed ID: 32599983
[TBL] [Abstract][Full Text] [Related]
11. Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications.
Ezzat S; Zheng L; Winer D; Asa SL
Mol Endocrinol; 2006 Nov; 20(11):2965-75. PubMed ID: 16857743
[TBL] [Abstract][Full Text] [Related]
12. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy.
Quintanal-Villalonga Á; Ferrer I; Guruceaga E; Cirauqui C; Marrugal Á; Ojeda L; García S; Zugazagoitia J; Muñoz-Galván S; Lopez-Rios F; Montuenga L; Vicent S; Molina-Pinelo S; Carnero A; Paz-Ares L
EBioMedicine; 2020 Mar; 53():102683. PubMed ID: 32114392
[TBL] [Abstract][Full Text] [Related]
13. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
[TBL] [Abstract][Full Text] [Related]
14. FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective.
Quintanal-Villalonga A; Molina-Pinelo S; Yagüe P; Marrugal Á; Ojeda-Márquez L; Suarez R; Ponce-Aix S; Enguita AB; Carnero A; Ferrer I; Paz-Ares L
Lung Cancer; 2019 May; 131():112-121. PubMed ID: 31027687
[TBL] [Abstract][Full Text] [Related]
15. BLU-554, A selective inhibitor of FGFR4, exhibits anti-tumour activity against gastric cancer in vitro.
Zhang X; Zhang X; Han R; Wang Z; Yang Q; Huang Y; Yan Y
Biochem Biophys Res Commun; 2022 Mar; 595():22-27. PubMed ID: 35093636
[TBL] [Abstract][Full Text] [Related]
16. FGF-1/-3/FGFR4 signaling in cancer-associated fibroblasts promotes tumor progression in colon cancer through Erk and MMP-7.
Bai YP; Shang K; Chen H; Ding F; Wang Z; Liang C; Xu Y; Sun MH; Li YY
Cancer Sci; 2015 Oct; 106(10):1278-87. PubMed ID: 26183471
[TBL] [Abstract][Full Text] [Related]
17. Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
Hatlen MA; Schmidt-Kittler O; Sherwin CA; Rozsahegyi E; Rubin N; Sheets MP; Kim JL; Miduturu C; Bifulco N; Brooijmans N; Shi H; Guzi T; Boral A; Lengauer C; Dorsch M; Kim RD; Kang YK; Wolf BB; Hoeflich KP
Cancer Discov; 2019 Dec; 9(12):1686-1695. PubMed ID: 31575540
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.
Lu X; Chen H; Patterson AV; Smaill JB; Ding K
J Med Chem; 2019 Mar; 62(6):2905-2915. PubMed ID: 30403487
[TBL] [Abstract][Full Text] [Related]
19. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling.
Pai R; Dunlap D; Qing J; Mohtashemi I; Hotzel K; French DM
Cancer Res; 2008 Jul; 68(13):5086-95. PubMed ID: 18593907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
